Amylyx's Drug Approval Path May Already Be Priced In—Or Not
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Amylyx typically reports earnings before the market open, meaning Day 0 represents the first full trading session where investors react to results, and Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-06 | +$2.34 (+10.71%) | $3.26 (14.92%) | -$1.37 (-5.66%) | $2.04 (8.43%) |
| 2026-05-07 | -$0.86 (-5.35%) | $1.28 (7.97%) | -$0.47 (-3.09%) | $0.95 (6.25%) |
| 2026-03-03 | -$1.19 (-7.78%) | $1.95 (12.73%) | +$0.94 (+6.66%) | $1.33 (9.43%) |
| 2025-11-06 | -$0.78 (-5.89%) | $0.97 (7.33%) | -$0.15 (-1.20%) | $0.65 (5.22%) |
| 2025-08-07 | -$0.35 (-4.27%) | $0.45 (5.49%) | -$0.20 (-2.55%) | $0.37 (4.72%) |
| 2025-05-08 | -$0.29 (-5.95%) | $0.93 (19.10%) | +$0.03 (+0.66%) | $0.42 (9.06%) |
| 2025-03-04 | +$0.01 (+0.33%) | $0.57 (19.00%) | +$0.35 (+11.63%) | $0.40 (13.29%) |
| 2024-11-07 | +$0.32 (+5.14%) | $1.14 (18.28%) | +$0.16 (+2.45%) | $0.89 (13.69%) |
| Avg Abs Move | 5.68% | 13.10% | 4.24% | 8.76% |
Historically, Amylyx has been a volatile earnings mover, with an average absolute Day 0 move of 5.68% and an average Day 0 range of 13.10%. The most dramatic reaction came in August 2026, when the stock surged 10.71% on Day 0 following the positive Phase 3 LUCIDITY data announcement, with an intraday range of nearly 15%.
Day +1 follow-through has been somewhat more muted, averaging a 4.24% absolute move with an 8.76% range. Notably, the stock has shown a tendency for reversals or consolidation after the initial reaction—such as the March 2026 report, where a 7.78% Day 0 decline was followed by a 6.66% Day +1 rebound.
Given the current setup—with the LUCIDITY data already public and the focus on execution and regulatory timelines—investors should expect meaningful volatility around this release, particularly if management provides concrete updates on the NDA filing or commercial strategy.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 16) |
| Expected Move | $2.04 (6.93%) |
| Expected Range | $27.38 to $31.46 |
| Implied Volatility | 66.89% |
The options market is pricing a 6.93% expected move for the November expiration, which is slightly above the historical average Day 0 move of 5.68% but well below the 13.10% average intraday range. This suggests the market is anticipating moderate volatility, though not as extreme as the August earnings reaction when the stock moved over 10%.
Part 3: What Analysts Are Saying
Current Analyst Consensus
Amylyx enjoys strong Wall Street support, with 12 Strong Buy ratings, 0 Moderate Buy ratings, and 2 Hold ratings—no analysts recommend selling the stock. The average recommendation of 4.71 out of 5.0 reflects overwhelming bullish sentiment. The consensus price target stands at $39.33, with a high estimate of $57.00 and a low of $20.00, implying substantial upside from the current price of $29.40.
Sentiment Trend
Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.71. This stability suggests analysts are maintaining their bullish stance following the August Phase 3 data readout and are awaiting the upcoming earnings call for further catalysts around regulatory submission timing and commercial execution.
Price Target Implications
The consensus target of $39.33 represents approximately 34% upside from current levels, reflecting confidence in the company's ability to execute on its NDA filing and secure approval for avexitide. The wide range between the low ($20.00) and high ($57.00) targets underscores the binary nature of clinical-stage biotech investing—success hinges on regulatory approval and commercial uptake, while setbacks could materially impact valuation.
Part 4: Technical Picture
Barchart Technical Opinion
The Barchart Technical Opinion signal currently stands at 56% Buy, unchanged from both one week ago and one month ago. This stable reading suggests the technical setup has been consolidating in a neutral-to-positive range as the stock digests gains from the August Phase 3 data announcement.
Timeframe Analysis
- Short-term (50% Buy): Neutral signal indicates near-term momentum is balanced, with the stock trading in a consolidation pattern ahead of earnings
- Medium-term (50% Buy): Neutral reading suggests the intermediate timeframe is also in equilibrium, reflecting a wait-and-see posture from traders
- Long-term (100% Buy): Strong buy signal reflects confidence in the longer-term trend, supported by the successful Phase 3 trial and upcoming regulatory milestones
Trend Characteristics: The combination of Average strength and Average direction suggests the stock is in a stable but unremarkable technical environment heading into earnings—neither overbought nor oversold, with no extreme momentum in either direction.
Moving Average Analysis
The stock is currently trading above its 5-day ($28.84), 10-day ($28.34), 20-day ($27.96), 100-day ($25.78), and 200-day ($20.29) moving averages, but below its 50-day moving average ($30.34). This configuration suggests the stock is in a short-term pullback within a longer-term uptrend—a common pattern as traders take profits following the August surge.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $28.84 | 50-Day MA | $30.34 |
| 10-Day MA | $28.34 | 100-Day MA | $25.78 |
| 20-Day MA | $27.96 | 200-Day MA | $20.29 |
The technical setup heading into earnings is cautiously supportive. The stock's position above most key moving averages—particularly the 100-day and 200-day—confirms the longer-term uptrend remains intact. However, the failure to hold above the 50-day moving average suggests some near-term hesitation, likely as investors await clarity on the NDA filing timeline and commercial strategy.
With the stock trading near $29.40 and the 50-day average at $30.34, a strong earnings report and positive regulatory update could quickly propel the stock back above this key resistance level. Conversely, any delays or disappointing commentary on the NDA submission could see the stock test support at the 20-day moving average around $27.96. The neutral RSI environment and balanced short- and medium-term signals suggest the stock is well-positioned to move in either direction based on the fundamental news flow from the earnings call.